NCMAG126 Nivolumab in combination with ipilimumab advice document: April 2026
Posted on:
Document Type
NCMAG advice
Process guidance
Summary
Nivolumab in combination with ipilimumab for the neoadjuvant treatment of adults with mismatch repair deficient or microsatellite instability-high locally advanced colon cancer classified as T4 or borderline resectable.
Decision: off label use is supported